Skip to main content

Search

Reset all filters
500 Result(s)
Sort by

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Investigating MDM2-p53 in cancer

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Sites Around the World

Sites Around the World

Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
Nick Gollop

Nick Gollop

Nick Gollop loves making a difference for patients and their families as a Senior Global Clinical Programme Leader in Clinical Development.
Galym Zhunisbekov

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Purchasing

Purchasing

Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Accessibility Statement

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.